Comorbidities in early-onset sporadic versus presenilin-1 mutation-associated Alzheimer disease dementia: Evidence for dependency on Alzheimer disease neuropathological changes
- PMID: 39656832
- PMCID: PMC11747142
- DOI: 10.1093/jnen/nlae122
Comorbidities in early-onset sporadic versus presenilin-1 mutation-associated Alzheimer disease dementia: Evidence for dependency on Alzheimer disease neuropathological changes
Erratum in
-
Correction to: Comorbidities in early-onset sporadic versus presenilin-1 mutation-associated Alzheimer disease dementia: Evidence for dependency on Alzheimer disease neuropathological changes.J Neuropathol Exp Neurol. 2025 Sep 1;84(9):844. doi: 10.1093/jnen/nlaf030. J Neuropathol Exp Neurol. 2025. PMID: 40249951 Free PMC article. No abstract available.
Abstract
Studying comorbidities in early onset Alzheimer disease (AD) may provide an advantageous perspective on their pathogenesis because aging factors may be largely inoperative for these subjects. We compared AD comorbidities between early-onset sporadic cases and American and Colombian cases with PSEN1 mutations. AD neuropathological changes (ADNC) were very severe in all groups but more severe in the PSEN1 groups. Lewy body disease and cerebral white matter rarefaction were the most common (up to 60%) of AD comorbidities, followed by arteriolosclerosis (up to 37%), and large-vessel atherosclerosis (up to 20%). Differences between the 3 groups included earlier age of onset in the American PSEN1 cases, shorter disease duration in sporadic cases, and more frequent large-vessel atherosclerosis and cerebral amyloid angiopathy in the Colombian PSEN1 cases. Logistic regression models adjusted for age and sex found the presence of a PSEN1 mutation, an apolipoprotein ε4 allele and TDP-43 pathology to predict an earlier age of onset; Hispanic ethnicity and multiracial subjects were predictive of severe CAA. Comorbidities are common in early onset AD and should be considered when planning clinical trials with such subjects. However, they may be at least partially dependent on ADNC and thus potentially addressable by anti-amyloid or and/anti-tau therapies.
Keywords: E280A; Lewy body; TDP-43; apolipoprotein E; autopsy; cerebral infarcts; clinical trial; white matter rarefaction.
© The Author(s) 2024. Published by Oxford University Press on behalf of American Association of Neuropathologists, Inc.
Conflict of interest statement
None declared.
Update of
-
Comorbidities in Early-Onset Sporadic versus Presenilin-1 Mutation-Associated Alzheimer's Disease Dementia: Evidence for Dependency on Alzheimer's Disease Neuropathological Changes.medRxiv [Preprint]. 2023 Aug 16:2023.08.14.23294081. doi: 10.1101/2023.08.14.23294081. medRxiv. 2023. Update in: J Neuropathol Exp Neurol. 2025 Feb 01;84(2):104-113. doi: 10.1093/jnen/nlae122. PMID: 37646002 Free PMC article. Updated. Preprint.
References
MeSH terms
Substances
Grants and funding
- R01 AG062479-01/NH/NIH HHS/United States
- P20 AG068053/AG/NIA NIH HHS/United States
- P30 AG066515/AG/NIA NIH HHS/United States
- P30 AG066508/AG/NIA NIH HHS/United States
- P30 AG066519/AG/NIA NIH HHS/United States
- P30 AG066462/AG/NIA NIH HHS/United States
- P30 AG066530/AG/NIA NIH HHS/United States
- R01 AG056058/AG/NIA NIH HHS/United States
- P30 AG066509/AG/NIA NIH HHS/United States
- P20 AG068077/AG/NIA NIH HHS/United States
- P30 AG066546/AG/NIA NIH HHS/United States
- P30 AG072972/AG/NIA NIH HHS/United States
- R01 AG062479/AG/NIA NIH HHS/United States
- P30 AG072979/AG/NIA NIH HHS/United States
- P20 AG068082/AG/NIA NIH HHS/United States
- P30 AG072975/AG/NIA NIH HHS/United States
- P30 AG066444/AG/NIA NIH HHS/United States
- P30 AG066507/AG/NIA NIH HHS/United States
- P30 AG072946/AG/NIA NIH HHS/United States
- P30 AG066518/AG/NIA NIH HHS/United States
- P30 AG066511/AG/NIA NIH HHS/United States
- U24 AG072122/AG/NIA NIH HHS/United States
- P30 AG066512/AG/NIA NIH HHS/United States
- P30 AG062421/AG/NIA NIH HHS/United States
- R01 AG075802/AG/NIA NIH HHS/United States
- P30 AG072978/AG/NIA NIH HHS/United States
- U24 AG072122/GF/NIH HHS/United States
- RF1 NS110048/NS/NINDS NIH HHS/United States
- P30 AG072980/AG/NIA NIH HHS/United States
- P30 AG062429/AG/NIA NIH HHS/United States
- P01AG025294/Joseph F. Arboleda-Velasquez
- P30 AG072973/AG/NIA NIH HHS/United States
- P30 AG062422/AG/NIA NIH HHS/United States
- R01 AG079280/AG/NIA NIH HHS/United States
- P30 AG072977/AG/NIA NIH HHS/United States
- P30 AG062677/AG/NIA NIH HHS/United States
- P20 AG068024/AG/NIA NIH HHS/United States
- P30 AG072958/AG/NIA NIH HHS/United States
- P30 AG062715/AG/NIA NIH HHS/United States
- P30 AG066506/AG/NIA NIH HHS/United States
- P30 AG072976/AG/NIA NIH HHS/United States
- P30 AG066468/AG/NIA NIH HHS/United States
- NACC
- P30 AG072947/AG/NIA NIH HHS/United States
- P30 AG072931/AG/NIA NIH HHS/United States
- P30 AG066514/AG/NIA NIH HHS/United States
- P30 AG072959/AG/NIA NIH HHS/United States
- NIA
- P01 AG025204/AG/NIA NIH HHS/United States